Forbius:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Forbius - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11245
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Forbius is a clinical stage pharmaceutical company that designs and develops biotherapeutics with selective anti-tumor properties for the treatment of cancer and fibrotic diseases. The company’s pipeline product portfolio includes AVID100, anti-EGFR antibody-drug conjugate for treating solid tumors; AVID200, Isoform-selective TGF- beta inhibitor neutralizing promotion of cancer metastasis, negative effects on hematopoiesis and cardiac toxicity; AVID300 targeting fibrosis and subcutaneous formulation; and AVID400. Its ADCs prevents the inadvertent destruction of normal tissues, unlike traditional chemotherapies, which leads to safe and effective anti-cancer treatment. The company also offers preclinical and early-stage clinical development of its proprietary compounds. Forbius is headquartered in Austin, Texas, the US.

Forbius – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forbius, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forbius, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forbius, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Forbius, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Formation Biologics Raises Funds through Series B Venture Financing 10
Formation Biologics to Raise USD1 Million in Venture Financing 11
AvidBiologics Raises Funds through Venture Financing 12
Formation Biologics Raises Funds through Seed Financing 13
Partnerships 14
AvidBiologics Enters Into Co-Development Agreement With National Research Council of Canada 14
Forbius – Key Competitors 15
Forbius – Key Employees 16
Forbius – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Corporate Communications 18
May 15, 2017: Formation Biologics Announces Appointment of Dr. Anthony Tolcher to its Board of Directors 18
Product News 19
05/15/2017: Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Forbius, Pharmaceuticals & Healthcare, Key Facts 2
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forbius, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forbius, Deals By Therapy Area, 2012 to YTD 2018 8
Forbius, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Formation Biologics Raises Funds through Series B Venture Financing 10
Formation Biologics to Raise USD1 Million in Venture Financing 11
AvidBiologics Raises Funds through Venture Financing 12
Formation Biologics Raises Funds through Seed Financing 13
AvidBiologics Enters Into Co-Development Agreement With National Research Council of Canada 14
Forbius, Key Competitors 15
Forbius, Key Employees 16
Forbius, Other Locations 17

List of Figures
Forbius, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forbius, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forbius, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Forbius:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nephros Inc (NEPH):医療機器:M&Aディール及び事業提携情報
    Summary Nephros Inc (Nephros) is dialysis device manufacturer. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters includes Endotoxin ten Cartridge filter, SSUmini, DSU-D and SSU-D. Nephros dialysis ultrafilters are intended …
  • Solo Oil plc (SOLO):企業の財務・戦略的SWOT分析
    Summary Solo Oil Plc (Solo Oil), formerly Immersion Technologies International Plc, is an oil and gas exploration and production company that acquires, explores, develops and produces oil and gas resource development and production assets. The company's non operated oil and gas assets portfolio incl …
  • Epuron Pty Ltd:電力:M&Aディール及び事業提携情報
    Summary Epuron Pty Ltd (Epuron), formerly Taurus Energy Pty Ltd, a subsidiary of Epuron Holding GmbH & Co KG, is a renewable energy company that develops wind and solar energy projects. The company provides resource monitoring and assessment for wind and solar energy projects including data capture …
  • Isagen SA ESP:企業の発電所・SWOT分析2018
    Isagen SA ESP - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Continental Grain Co:企業の戦略的SWOT分析
    Continental Grain Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Abraxas Petroleum Corp (AXAS):石油・ガス:M&Aディール及び事業提携情報
    Summary Abraxas Petroleum Corp (Abraxas) is an oil and gas company. The company offers exploration, production and development of oil and gas properties across the US. Its properties are located in Mid-Continent, Rocky Mountain, Gulf Coast and Permian Basin regions of the US. Abraxas’s Permian basin …
  • Chuo Kagaku Co., Ltd.:企業の戦略・SWOT・財務情報
    Chuo Kagaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chuo Kagaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Genetic Analysis AS:製品パイプライン分析
    Summary Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of diseases related to dysbiosis and ba …
  • Cantel Medical Corp (CMD):医療機器:M&Aディール及び事業提携情報
    Summary Cantel Medical Corp (Cantel) is a provider of infection prevention and control products and services for the healthcare market. Its product portfolio includes endoscopy procedure disposables, medical device reprocessing systems, detergents, disinfectants, water purification systems, filtrati …
  • Kuwait Food Company (Americana) K.S.C.P. (FOOD):企業の財務・戦略的SWOT分析
    Kuwait Food Company (Americana) K.S.C.P. (FOOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • True Diagnostics Inc:製品パイプライン分析
    Summary True Diagnostics Inc (True Diagnostics) is a research, development and manufacturing company that offers in-vitro immunodiagnostic test systems and reagents. The company provides trueDX platform technology including trueDX reader, trueDX software, trueDX-TSH test, trueDX-T4 test, trueDX-Gneg …
  • Essilor International S.A.:企業の戦略・SWOT・財務情報
    Essilor International S.A. - Strategy, SWOT and Corporate Finance Report Summary Essilor International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • EDF Energy Holdings Ltd:企業の戦略的SWOT分析
    EDF Energy Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • PDC Energy Inc (PDCE):石油・ガス:M&Aディール及び事業提携情報
    Summary PDC Energy Inc (PDC Energy) is an oil and gas company that offers production, development, exploration and marketing of crude oil, natural gas and natural gas liquids. The company provides horizontal drilling and low-risk organic development of oil and natural gas reserves from shales and ti …
  • Sonic Healthcare Limited:企業の戦略・SWOT・財務分析
    Sonic Healthcare Limited - Strategy, SWOT and Corporate Finance Report Summary Sonic Healthcare Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zest Dental Solutions:医療機器:M&Aディール及び事業提携情報
    Summary Zest Dental Solutions (Zest Dental), formerly ZEST Anchors LLC is a medical device manufacturing company that manufactures, develops, and distributes dental solutions for the treatment of edentulous patients. The company’s products include dental removal tool, attachment processing materials …
  • Guangzhou Institute of Biomedicine and Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Institute of Biomedicine and Health (GIBH) is a research institute that develops protocols for disease control and prevention. The institute conducts research in the areas of stem cell and regenerative medicine, chemical biology, immunology and infectious diseases, public health, a …
  • Difference Capital Financial Inc.:企業のM&A・事業提携・投資動向
    Difference Capital Financial Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Difference Capital Financial Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Kwality Group:企業の戦略・SWOT・財務分析
    Kwality Group - Strategy, SWOT and Corporate Finance Report Summary Kwality Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Etiqa General Insurance Berhad:企業の戦略的SWOT分析
    Etiqa General Insurance Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆